Skip to main content
. 2020 Aug 6;35(11):1966–1976. doi: 10.1002/mds.28219

FIG. 2.

FIG. 2.

Gastrointestinal symptoms and related QoL change after intervention. The efficacy of DA‐9701 was demonstrated in the NDI‐K QoL scores at 4 weeks compared with the placebo (adjusted P = 0.023 by a linear mixed effect model analysis). Time changes at 4 and 12 weeks in the NDI‐K QoL scores were significant in the DA‐9701 group. There were also significant time changes in the NDI‐K total symptom scores and dyspepsia sum scores in the DA‐9701 group at 12 weeks. The placebo group also showed significant time changes in the NDI‐K symptom total score and dyspepsia scores after an additional 8 weeks of DA‐9701 therapy while maintaining double blindness until the end of the trial. P values provided in each figure are comparisons between DA‐9701 and the placebo groups at 4 weeks. Asterisks designate statistically significant temporal changes in the scores in each group: * < 0.05, ** < 0.01, *** < 0.001. NDI‐K, The Nepean Dyspepsia Index–Korean version; QoL, quality of life.